digital health companies glp-1 programs Technologies enabling long-term outcomes for users Noom Launches Microdose GLP-1 Program,

All clinical trials of new medicines in New Zealand require approval from Medsafe and an ethics committee, and Medsafe has not approved any clinical trials in New Zealand for these products

Preserve & Build Muscle Mass Staying active on GLP-1 medications is key to preserving muscle mass

It promotes angiogenesis (the formation of new blood vessels), enhances tissue repair, and exhibits powerful anti-inflammatory properties

Silymarin has been shown to promote alkaline phosphatase activity of osteoblasts and inhibit tartrate-resistant acid phosphatase activity of osteoclasts

- L-

The study, published in JAMA , found these adverse gastrointestinal effects happen in non-diabetic patients using the drugs specifically for weight loss